Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02557724 · ClinicalTrials.gov registry record
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
A clinical trial of Liver Failure and Liver Neoplasm, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT02557724 is a study of Liver Failure and Liver Neoplasm that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 35 participants, below the 164-participant average among 7 other Liver Failure trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02557724, a study of Liver Failure and Liver Neoplasm, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
To study if the administration of corticoid hinder or enhance the mobilization of Mesenchymal Stem Cells (MSCs) in the peripheral blood during liver transplantation and whether this affects the outcome with respect to graft versus host response.
Conditions Studied
Interventions
- PROCEDURE blood samples
Study Locations (1)
New Jersey
- University Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02557724
The ClinicalTrials.gov registry entry for NCT02557724 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 7 other Liver Failure trials with a reported enrollment target (79% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Liver Failure appearing as the primary indexed condition, and to 1 intervention - of which blood samples is the first listed.
NCT02557724 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02557724 about?
NCT02557724 is a clinical study titled "Mobilization of Mesenchymal Stem Cells During Liver Transplantation". To study if the administration of corticoid hinder or enhance the mobilization of Mesenchymal Stem Cells (MSCs) in the peripheral blood during liver transplantation and whether this affects the outcome with respect to graft versus host response.
What is the current status of trial NCT02557724?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2015-09. Estimated completion is 2017-07.
What conditions does trial NCT02557724 study?
This clinical trial studies the following conditions: Liver Failure, Liver Neoplasm.
What interventions are being tested in trial NCT02557724?
The interventions under investigation include: blood samples (PROCEDURE).
Who is sponsoring clinical trial NCT02557724?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02557724 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
RECRUITING · Phase 1
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
-
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
-
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
COMPLETED · NA
-
A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.